TMO
Thermo Fisher Scientific Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$608.30
−1.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 46.3B | 44.6B | 42.9B | 42.9B | 44.9B |
| Cost of Revenue | 27.6B | 27.8B | 25.2B | 25.7B | 25.9B |
| Gross Profit | 18.7B | 16.8B | 17.7B | 17.2B | 19.0B |
| Operating Expenses | |||||
| R&D Expense | 1.4B | 1.4B | 1.4B | 1.3B | 1.5B |
| SG&A Expense | 8.0B | 7.3B | 8.7B | 8.4B | 9.0B |
| General & Admin Expense | 1.9B | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.1B | — | — | — | — |
| Total Operating Expenses | 10.5B | 8.7B | 10.1B | 9.7B | 10.5B |
| Cost and Expenses | 38.1B | 36.4B | 35.2B | 35.4B | 36.4B |
| Operating Income (EBIT) | 8.2B | 8.1B | 7.7B | 7.4B | 8.5B |
| Non-Operating | |||||
| Interest Income | 932.0M | 993.0M | 1.1B | 879.0M | 272.0M |
| Interest Expense | 1.5B | 1.4B | 1.7B | 1.5B | 726.0M |
| Net Interest Income | (535.0M) | (426.0M) | (576.0M) | (612.0M) | (454.0M) |
| Other Non-Op Income/Expense | (586.0M) | (842.0M) | (667.0M) | (1.2B) | (862.0M) |
| Non-Operating Income (excl Interest) | (427.0M) | (577.0M) | (1.0B) | (343.0M) | (36.0M) |
| EBT (Pre-Tax Income) | 7.6B | 7.3B | 7.0B | 6.2B | 7.7B |
| Income Tax Expense | 597.0M | 547.0M | 657.0M | 284.0M | 703.0M |
| Bottom Line | |||||
| Net Income | 7.0B | 6.7B | 6.3B | 6.0B | 7.0B |
| Earnings from Cont. Ops | 7.0B | 6.7B | 6.3B | 6.0B | 7.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 7.0B | 6.7B | 6.3B | 6.0B | 7.0B |
| Per Share | |||||
| Basic EPS | $18.62 | $17.77 | $16.58 | $15.53 | $17.73 |
| Diluted EPS | $18.59 | $17.74 | $16.53 | $15.45 | $17.64 |
| Revenue Per Share | $124.89 | $118.50 | $112.25 | $111.03 | $114.58 |
| Shares | |||||
| Basic Shares Outstanding | 371.0M | 376.0M | 382.0M | 386.0M | 392.0M |
| Diluted Shares Outstanding | 371.0M | 377.0M | 383.0M | 388.0M | 394.0M |
| Profitability Metrics | |||||
| EBITDA | 10.9B | 11.5B | 11.8B | 11.2B | 11.9B |
| D&A | 2.3B | 2.8B | 3.1B | 3.4B | 3.4B |
| EBIT | 8.6B | 8.7B | 8.7B | 7.8B | 8.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026